Product
SARS-CoV-2 Bivalent mRNA vaccine
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Multi-center, Randomized, Blinded, Placebo-controlled, Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) as Booster in Participants Aged 18 Years and Older Who Completed Primary/1 Booster Dose(s) of SARS-CoV-2 VaccinationStatus: Recruiting, Estimated PCD: 2024-03-01